Clinical Trial Search

Primary: Median Overall Survival (OS) — 7.1 Months

Primary: Overall Survival (OS) — 9.38; 14.7 Months

Primary: Response Rate — .125 proportion of participants

Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization. — 41; 39; 30 Participants

Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months

Primary: Median Overall Survival — 4.7 months

Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001

Primary: Objective Response (OR = CR or PR) as Determined by the RECIST Criteria — 0; 1 participants

Primary: 2-month Progression-Free Survival Rate — 10; 10 percentage of patients

Primary: Overall Survival — 4.2; 8.3 months — p=0.36

Primary: Progression-free Survival — 5.7 months

Primary: Rate of Participants Achieving Complete Response or Partial Response to Therapy. — 6; 25; 0 participants

Primary: Overall Survival (OS) — 210; 171 Days — p=0.1026

Primary: Maximum Tolerated Dose (MTD) of Epacadostat — 600 mg BID

Primary: Progression-free Survival — 2 Participants

Primary: Progression Free Survival — 2.07 months

Primary: To Determine the Dose Limiting Toxicities — 27 participants

Primary: Six Month Survival — 11 percentage of patients

Primary: Safety of Combining the Pancreatic Tumor Vaccine in Sequence With Cyclophosphamide and Erbitux. Safety is Defined as the Number of Treatment-related Grade 3 or 4 Adverse…

Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants

Primary: Number of Participants With Progressive Disease, — 2 Participants

Primary: Overall Response Rate — 1 Participants

Primary: Late Gastrointestinal Toxicities — 13 Participants

Primary: Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months — 78.6; 30 percentage of participants

Primary: Overall Survival — 8.4; 6.7 months — p=0.352

Primary: Progression-free Survival — 2.5; 4.0 months — p=0.15

Primary: Number of Patients Progression Free and Surviving at 16 Weeks as a Percent of All Enrolled Subjects — 2 Participants — p=0.824

Primary: Objective Response Rate (ORR) Using Immune RECIST (iRECIST) Criteria — 0 Participants

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Proportion of Patients With Objective Response Evaluated by RECIST (Solid Tumor Response Criteria) — 0.045; 0.07 Proportion of participants